Consolida Regalis Flower

Dosage for Consolida Regalis Flower allergenic extract is highly individualized and must be determined by an allergist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Skin Testing Dosage

• Skin Prick Test: Usually a single drop of a 1:20 w/v or 1:10 w/v concentration is applied to the skin.
• Intradermal Test: If the prick test is negative, a more sensitive intradermal injection of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) may be used.

Immunotherapy Dosage (SCIT)

Immunotherapy follows a two-phase schedule:

1. 1Build-up Phase: Injections start at a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution). Doses are increased weekly or bi-weekly over 3 to 6 months until the maintenance dose is reached.
2. 2Maintenance Phase: Once the effective therapeutic dose is reached, injections are given less frequently, typically every 2 to 4 weeks. A common maintenance volume is 0.5 mL of a 1:100 w/v or 1:20 w/v concentration.

Consolida Regalis Flower extract is generally considered safe for use in children, typically starting at age 5. Dosing protocols are similar to adult protocols but may be adjusted based on the child's weight and the severity of their allergic symptoms. Very young children may be less cooperative with frequent injections, which should be considered before starting a multi-year immunotherapy plan.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is composed of proteins that are naturally degraded. However, the patient's overall health must be stable to manage potential systemic reactions.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (the treatment for anaphylaxis) may pose higher risks in this population. Healthcare providers may opt for a more conservative build-up schedule.

• Administration Site: Injections for immunotherapy must be given subcutaneously in the outer aspect of the upper arm. They should never be given intravenously.
• Observation Period: Patients must remain in the doctor's office for at least 30 minutes after every injection to monitor for signs of a systemic allergic reaction.
• Timing: Injections should be delayed if the patient is experiencing an acute asthma flare or has a significant fever/infection.
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose in the build-up phase is missed, the next dose may need to be reduced to ensure safety.

• Missed 1 week: Usually, the same dose is repeated.
• Missed 2-3 weeks: The dose is typically reduced by one or two steps in the schedule.
• Missed >4 weeks: The schedule may need to be restarted or significantly rolled back. Consult your allergist immediately.

An overdose of allergenic extract usually manifests as a severe systemic allergic reaction or anaphylaxis.

• Signs: Hives, swelling of the throat, wheezing, rapid pulse, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (EpiPen), followed by oxygen, IV fluids, and antihistamines. If an overdose occurs during an office visit, the medical staff will initiate emergency protocols.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these injections without medical guidance.

Most patients receiving Consolida Regalis Flower extract will experience local reactions at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Swelling (Wheal): A raised, itchy bump at the injection site that usually appears within minutes and resolves within a few hours.
• Erythema (Redness): Redness surrounding the injection site, which may feel warm to the touch.
• Pruritus (Itching): Intense itching at the site of the skin test or injection.
• Delayed Local Reactions: Swelling or redness that appears 6 to 24 hours after the injection. This is common and usually managed with ice packs or OTC antihistamines.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Nasal Congestion: A 'stuffy' feeling or sneezing shortly after administration.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy session.
• Headache: Mild to moderate tension-type headaches.

• Angioedema: Deep tissue swelling, often affecting the lips, eyelids, or extremities.
• Persistent Cough: A dry, hacking cough that may indicate mild airway irritation.
• Gastrointestinal Upset: Nausea or abdominal cramping, which can be an early sign of a systemic reaction.

> Warning: Stop taking Consolida Regalis Flower and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or shortness of breath.
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing.
• Hypotension (Low Blood Pressure): Feeling faint, dizzy, or passing out.
• Cyanosis: Bluish tint to the lips or fingernails, indicating low oxygen levels.
• Rapid or Weak Pulse: Heart palpitations or a sense of impending doom.

There are no known long-term toxicities associated with Consolida Regalis Flower extract when used as directed. The primary 'long-term' effect is the desired modulation of the immune system. However, repeated local reactions over many years can occasionally lead to minor skin thickening (induration) at the injection sites. There is no evidence that allergenic extracts cause autoimmune diseases or cancer.

While Consolida Regalis Flower specifically may not have a unique black box warning, the class of allergenic extracts carries a standard FDA-mandated warning regarding anaphylaxis:

WARNING: RISK OF SEVERE ALLERGIC REACTION

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Do not administer if the patient has severe, unstable, or uncontrolled asthma.
• Patients must be observed for at least 30 minutes in a medical facility equipped with emergency supplies (epinephrine, oxygen, airway management).
• Patients with certain medical conditions or those taking beta-blockers may be at increased risk and may not respond to standard rescue treatments.

Report any unusual symptoms to your healthcare provider immediately. Even a 'mild' systemic reaction (like hives) should be reported, as it may predict a more severe reaction at the next dose.

Consolida Regalis Flower allergenic extract is intended for use only by physicians specialized in allergy and immunology. Because the extract contains active allergens, the risk of a systemic reaction is always present. Patients must be in relatively good health at the time of injection. If you are feeling ill, have a fever, or are experiencing an asthma flare-up, notify your nurse or doctor before receiving your shot.

No specific FDA black box warning exists solely for the Consolida Regalis species, but it falls under the general black box warning for all Non-Standardized Allergenic Extracts. This warning emphasizes that these products can cause anaphylaxis and must only be administered by healthcare professionals prepared to manage life-threatening emergencies. The warning also notes that the potency of non-standardized extracts is not compared to a national standard, meaning different manufacturers' products may vary in strength.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. The risk is highest during the build-up phase and during peak pollen seasons for the specific plant.
• Asthma Status: Patients with uncontrolled asthma are at a significantly higher risk for a fatal reaction. Lung function (peak flow) may be checked before administration.
• Cardiovascular Disease: Patients with heart conditions may not tolerate the stress of a systemic reaction or the effects of the epinephrine required to treat it.
• Autoimmune Disorders: Use with caution in patients with active autoimmune diseases, as immunotherapy might theoretically exacerbate these conditions, though data is limited.

• Pre-Injection Check: Patients should be asked about any late reactions from the previous dose and their current asthma status.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is standard protocol.
• Periodic Re-evaluation: Every 6-12 months, the allergist will review the patient's symptom improvement and may perform repeat skin testing to assess the level of desensitization.

Most patients can drive after their 30-minute observation period. However, if a patient experiences a systemic reaction or is given antihistamines/epinephrine, they should not drive or operate machinery until the symptoms and the effects of the rescue medications have completely resolved.

Alcohol should be avoided on the day of an injection. Alcohol causes vasodilation (widening of blood vessels), which can potentially increase the rate of allergen absorption and increase the risk or severity of a systemic reaction.

Immunotherapy is typically a 3-to-5-year commitment. Stopping early may result in the return of allergic symptoms. There is no 'withdrawal syndrome' from allergenic extracts, but the clinical benefits will gradually diminish if the maintenance phase is not completed.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Consolida Regalis Flower.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are generally contraindicated or used with extreme caution. Beta-blockers can make an allergic reaction more severe and, more importantly, they can block the effects of epinephrine, making it difficult to treat anaphylaxis if it occurs.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process adrenaline/epinephrine, potentially leading to dangerous blood pressure spikes during emergency treatment.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions during immunotherapy.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the effects of epinephrine, complicating the management of a reaction.

• Antihistamines (e.g., Loratadine, Cetirizine): While not dangerous, antihistamines must be stopped several days before diagnostic skin testing, as they will suppress the 'wheal and flare' response, leading to a false-negative result. They do not need to be stopped for immunotherapy injections.
• Systemic Corticosteroids: High doses of steroids may suppress the immune response to the extract, potentially reducing the efficacy of the desensitization process.

• Large/Heavy Meals: It is recommended to avoid very large or spicy meals immediately before or after an injection, as gastrointestinal distress can be confused with the early stages of an allergic reaction.
• Alcohol: As mentioned, alcohol can increase the risk of systemic reactions by increasing blood flow and absorption rates.

• St. John's Wort: May have minor interactions with the way the body handles stress and inflammation, though no specific contraindication exists.
• Herbal Stimulants: Products containing ephedra or high caffeine should be avoided as they can complicate heart rate monitoring during a reaction.

• Skin Testing: Consolida Regalis Flower extract will interfere with any other skin tests being performed simultaneously if the reactions overlap.
• IgE Testing: Treatment with the extract will eventually change the levels of specific IgE and IgG4 in the blood, which is an expected pharmacological effect rather than an 'interference.'

For each major interaction, the primary concern is either the masking of diagnostic results or the interference with the safety profile of the treatment. The management strategy usually involves a thorough medication review by the allergist before the first dose is administered.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.

Consolida Regalis Flower extract must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) consistently below 70% of predicted are at an unacceptably high risk for fatal bronchospasm during a reaction.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The cardiovascular system must be stable to handle potential anaphylaxis.
3. 3Prior Severe Reaction: If a patient has had a near-fatal reaction to Consolida Regalis or a very closely related Ranunculaceae extract, the risks of continuing often outweigh the benefits.
4. 4Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young infants or those with severe cognitive impairment) are generally not candidates for SCIT.

These conditions require a careful risk-benefit analysis by the specialist:

• Pregnancy: Immunotherapy should generally not be started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia. However, if a patient is already at a stable maintenance dose and is tolerating it well, the treatment may be continued.
• Autoimmune Diseases in Flare: Conditions like Lupus or Rheumatoid Arthritis should be stable before administering allergenic extracts.
• Beta-Blocker Therapy: If the medication cannot be switched to an alternative, the allergist must weigh the necessity of the allergy treatment against the risk of epinephrine resistance.

Patients allergic to Consolida Regalis Flower may show cross-sensitivity to other members of the Ranunculaceae family, such as:

• Delphinium (Larkspur)
• Ranunculus (Buttercups)
• Anemone

If you have had a severe reaction to any of these plants, you must inform your doctor before skin testing with Consolida Regalis.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Consolida Regalis Flower.

Pregnancy Category C: There are no adequate and well-controlled studies of Consolida Regalis Flower extract in pregnant women. The primary risk to the fetus is not the extract itself, but the potential for maternal anaphylaxis, which can cause a sudden drop in blood pressure and uterine blood flow, leading to fetal distress or miscarriage.

• Initiation: Starting immunotherapy during pregnancy is not recommended.
• Maintenance: If the mother is already on a stable maintenance dose, many allergists continue treatment as the risk of a reaction is lower once maintenance is reached.

It is generally considered safe to continue Consolida Regalis Flower immunotherapy while breastfeeding. The allergenic proteins are broken down in the mother's tissues and are not expected to pass into breast milk in any significant or harmful quantity. There are no known adverse effects on the nursing infant.

Consolida Regalis Flower is commonly used in children. Clinical guidelines suggest that immunotherapy is most effective when started early in the 'allergic march' to prevent the development of asthma.

• Age Limit: Usually not recommended for children under age 5 because they may be unable to communicate the early 'aura' of a systemic reaction.
• Dosing: Doses are titrated carefully. Pediatric patients must be monitored just as strictly as adults.

Patients over age 65 may receive Consolida Regalis Flower extract, but the physician must consider the 'whole patient.'

• Cardiovascular Reserve: Older adults are more likely to have underlying heart disease, making them more vulnerable to the effects of anaphylaxis or the adrenaline used to treat it.
• Polypharmacy: Increased likelihood of being on beta-blockers or ACE inhibitors, which complicates safety.

No specific studies have been conducted in patients with renal failure. However, since the product consists of natural proteins that are enzymatically degraded, renal impairment is not a contraindication. Dosage adjustments based on GFR are not typically required.

There is no evidence that hepatic impairment affects the safety or efficacy of Consolida Regalis Flower extract. The liver is not the primary site of clearance for these allergenic proteins.

> Important: Special populations require an individualized medical assessment. Always inform your doctor if you become pregnant while receiving allergy shots.

Consolida Regalis Flower extract acts as a biological modifier. In sensitive individuals, the primary allergens (proteins) in the extract bind to IgE antibodies on mast cells and basophils. This is the diagnostic mechanism. Therapeutically, repeated exposure via subcutaneous injection induces 'immunological tolerance.' This involves:

1. 1T-Cell Deviation: Shifting from a Th2 (allergic) response to a Th1 response.
2. 2T-Regulatory Cell Induction: Increasing IL-10 and TGF-beta, which suppress allergic inflammation.
3. 3B-Cell Switching: Promoting the production of IgG4 (blocking antibodies) instead of IgE.

• Onset of Action: For skin testing, the onset is 15-20 minutes. For immunotherapy, clinical improvement typically takes 6 to 12 months of consistent treatment.
• Duration of Effect: Diagnostic effects last only a few hours. Therapeutic effects can last for years after the completion of a 3-5 year course of immunotherapy.
• Tolerance: The goal is to induce long-term immunological tolerance, not pharmacological tolerance (where a drug stops working).

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | N/A (Allergenic proteins) |

| Half-life | Varies by protein (minutes to hours locally) |

| Tmax | 15-30 minutes (systemic absorption peak) |

| Metabolism | Proteolysis (Protease enzymes) |

| Excretion | Renal (Peptide fragments) |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides extracted from the flower of Consolida regalis.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic fractions.
• Solubility: Highly soluble in aqueous solutions and 50% glycerin.
• Structure: Natural plant proteins; non-synthetic.

Consolida Regalis Flower belongs to the class of Allergenic Extracts. It is specifically a non-standardized plant extract. Related medications include extracts for Ragweed, Timothy Grass, and Oak Pollen, which function via the same immunological principles.